SCHEMBL1462953

SCHEMBL1462953

O=C(Nc1cc(C(F)(F)F)ccc1O)Nc1ccccc1C(F)(F)F

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.77
KMT2A Q03164 4/20 0.77
CHRNA7 P36544 1/20 0.60
KDM4E B2RXH2 2/20 0.56
TRPV1 Q8NER1 2/20 0.55
ALDH1A1 P00352 2/20 0.54
TSHR P16473 1/20 0.54
TMPRSS4 Q9NRS4 1/20 0.54
NTRK1 P04629 1/20 0.54
CDK19 Q9BWU1 1/20 0.54
GRIK1 P39086 3/20 0.52
POLB P06746 2/20 0.50
MAPK1 P28482 1/20 0.50
RAB9A P51151 2/20 0.49
NPC1 O15118 1/20 0.49
THRB P10828 1/20 0.49
NOX1 Q9Y5S8 1/20 0.49
LMNA P02545 1/20 0.48
KDR P35968 1/20 0.48
MAPT P10636 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1462428 0.88 MEN1 (1.00) MEN1KMT2ACHRNA7TRPV1TMPRSS4
SCHEMBL29389109 0.88 MEN1 (1.00) MEN1KMT2ACHRNA7TRPV1TMPRSS4
SCHEMBL17691076 0.86 MEN1 (0.77) MEN1KMT2ACHRNA7KDM4ETRPV1
SCHEMBL6567619 0.85 KMT2A (0.65) MEN1KMT2AKDM4ETRPV1ALDH1A1
SCHEMBL7491295 0.84 MEN1 (0.75) MEN1KMT2ACHRNA7TRPV1NTRK1
SCHEMBL1462989 0.84 GRIK1 (0.72) MEN1KMT2ACHRNA7KDM4ETRPV1
SCHEMBL5595116 0.84 MEN1 (0.75) MEN1KMT2ACHRNA7TRPV1NTRK1
SCHEMBL8372104 0.82 MEN1 (0.71) MEN1KMT2ACHRNA7KDM4ETRPV1
SCHEMBL7490014 0.82 MEN1 (0.71) MEN1KMT2ACHRNA7TRPV1NTRK1
SCHEMBL1463353 0.81 MAPK14 (0.57) MEN1KMT2AKDM4EALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110071164-A1 ERG CHANNEL OPENERS FOR THE TREATMENT OF CARDIAC ARRHYTHMIAS OLESEN SOEREN PETER 2011-03-24 US claimed
EP-1663192-B1 hERG1 CHANNEL OPENERS FOR THE TREATMENT OF CARDIAC ARRHYTHMIAS NEUROSEARCH AS (DK) 2008-12-03 EP claimed
US-20060281794-A1 Erg channel openers for the treatment of cardiac arrhythmias NEUROSEARCH A/S (DK) 2006-12-14 US claimed
CN-1845726-A Erg channel openers for the treatment of cardiac arrhythmias POSEIDON PHARMACEUTICALS AS (DK) 2006-10-11 CN claimed
EP-1663192-A1 ERG CHANNEL OPENERS FOR THE TREATMENT OF CARDIAC ARRHYTHMIAS Poseidon Pharmaceuticals A/S (DK) 2006-06-07 EP claimed
WO-2005023237-A1 ERG CHANNEL OPENERS FOR THE TREATMENT OF CARDIAC ARRHYTHMIAS POSEIDON PHARMACEUTICALS A/S (DK) 2005-03-17 WO claimed
WO-2005023238-A1 ERG CHANNEL OPENERS FOR THE TREATMENT OF HYPEREXCITABILITY-RELATED NEURONAL DISEASES POSEIDON PHARMACEUTICALS A/S (DK) 2005-03-17 WO claimed
US-20110071164-A1 ERG CHANNEL OPENERS FOR THE TREATMENT OF CARDIAC ARRHYTHMIAS OLESEN SOEREN PETER 2011-03-24 US disclosed
US-7851492-B2 ERG channel openers for the treatment of cardiac arrhythmias NEUROSEARCH A/S (DK) 2010-12-14 US disclosed
EP-1663192-B1 hERG1 CHANNEL OPENERS FOR THE TREATMENT OF CARDIAC ARRHYTHMIAS NEUROSEARCH AS (DK) 2008-12-03 EP disclosed
US-20060281794-A1 Erg channel openers for the treatment of cardiac arrhythmias NEUROSEARCH A/S (DK) 2006-12-14 US disclosed
CN-1845726-A Erg channel openers for the treatment of cardiac arrhythmias POSEIDON PHARMACEUTICALS AS (DK) 2006-10-11 CN disclosed
EP-1663192-A1 ERG CHANNEL OPENERS FOR THE TREATMENT OF CARDIAC ARRHYTHMIAS Poseidon Pharmaceuticals A/S (DK) 2006-06-07 EP disclosed
WO-2005023238-A1 ERG CHANNEL OPENERS FOR THE TREATMENT OF HYPEREXCITABILITY-RELATED NEURONAL DISEASES POSEIDON PHARMACEUTICALS A/S (DK) 2005-03-17 WO disclosed
WO-2005023237-A1 ERG CHANNEL OPENERS FOR THE TREATMENT OF CARDIAC ARRHYTHMIAS POSEIDON PHARMACEUTICALS A/S (DK) 2005-03-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060281794-A1 Erg channel openers for the treatment of cardiac arrhythmias KCNJ2, KCNN3, KCNE1 MEN1 2084/4885KMT2A 2189/4885CHRNA7 170/4885
US-20110071164-A1 ERG CHANNEL OPENERS FOR THE TREATMENT OF CARDIAC ARRHYTHMIAS KCNJ2, KCNN3, KCNE1 MEN1 2084/4885KMT2A 2189/4885CHRNA7 170/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.